{"name":"Forte Biosciences, Inc.","slug":"forte-biosciences-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":36000,"revenueGrowth":-99.8,"grossMargin":0,"rdSpend":45299000,"netIncome":-69375000,"cash":76957000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2019"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"FB102","genericName":"FB102","slug":"fb102","indication":"Type 2 diabetes","status":"phase_2"}]}],"pipeline":[{"name":"FB102","genericName":"FB102","slug":"fb102","phase":"phase_2","mechanism":"FB102 is a small molecule that targets the SGLT2 receptor.","indications":["Type 2 diabetes"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMikgJBVV95cUxNRkFSNExIa2RvRnp6Sl9BWjJEWDNTM2twT3U5TFU0ME53cVRPdThSN0xQUnBGVHo0MnpJRHhjWFR5RWxTZ1VGNElrNDR0blZtaU1yT0ROOVBqdS1oM2dlLTJiTEtmZ0pJal9OTGdEOEoyWWlkeWVJLWhxZi1qdmpjQ0JfVUlYV2R2U2YxN1VfNzdhSWhfVWFNRkxIOEdYTERwSGRyenhZME5DOWN3SlU1TEJybWx5bjlWcnNjRFNaNFdQcTFmMWFBT2NFN0JTR3V2dzIxWDZweTRIdHp4enlacDZ0cGc5TWhPeGZVQ09zMi1hemlHcHAwR0RyYnh2WlJoWGpIWHE5OXZvUDU2VVlmSWdB?oc=5","date":"2026-04-02","type":"pipeline","source":"The Globe and Mail","summary":"Analysts Offer Insights on Healthcare Companies: Tvardi Therapeutics (TVRD) and Forte Biosciences (FBRX) - The Globe and Mail","headline":"Analysts Offer Insights on Healthcare Companies: Tvardi Therapeutics (TVRD) and Forte Biosciences (FBRX)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE1NZTVrdzNIbzRxUUNZX1d1LTJfR2ZPM214Tks4d2l6QWNrTy1UZVhiWjFzNXlfM2hNbjY0bUtGbDRtcmg1SUN4TC1jWlZBQXRCWmtmN0VOVEdPSG1la3Iw?oc=5","date":"2026-04-02","type":"pipeline","source":"ChartMill","summary":"FBRX Stock Price, Quote & Chart | FORTE BIOSCIENCES INC (NASDAQ:FBRX) - ChartMill","headline":"FBRX Stock Price, Quote & Chart | FORTE BIOSCIENCES INC (NASDAQ:FBRX)","sentiment":"neutral"},{"date":"2026-04-01","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisgFBVV95cUxOQmtCakRPTHNXbXpXRWc2NEZPbkhnWGx4VDNKSm1nWkFkVFc5SWVXeDNZRkxZNkZzdjRDUF9vWFJoanJ3V2RJX0FmX3VqYkJKd19ZUU5wOXVabGlzMzNkdnJFTHhuQ3I5YVE3aUtKTklrTGtHRFhFSndwVlpFMVJjNkF0VGVhal9oQ0hGdzBYZFgzanNRTldKeGFwVTN3VWZTQUVFeS1FdVpPeUxZRVFvcUJR?oc=5","date":"2026-03-31","type":"trial","source":"Stock Titan","summary":"Three FB102 disease readouts are due in 2026 after Forte spent $58M - Stock Titan","headline":"Three FB102 disease readouts are due in 2026 after Forte spent $58M","sentiment":"neutral"},{"date":"2026-03-31","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxQVWM0N3BpZC1ULWF0aFBnSTBQOTlfblZScXYwdTBLZE8tVGVFRmRsZWttUERDVkJiVkRjQUNCRzUwSkdOWEtVejhKMGdCZU5NUmx2LXJDQ1pTRzA5ek5vdHkyYnFSNzV4SkwzU1JLMEFFZ09zV2FFaDBSQklhYm4za01LUTVwRHJjNXk5QWJWMTZ5ZTdZaGdQTmxNM0xaWU5hanlUVTdpSnBYS0VpVEUxSUxYQXBPRE5fOGpn?oc=5","date":"2026-03-18","type":"pipeline","source":"Benzinga","summary":"12 Health Care Stocks Moving In Wednesday's After-Market Session - Benzinga","headline":"12 Health Care Stocks Moving In Wednesday's After-Market Session","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwAFBVV95cUxPSGp0djNFSTRtMDZlVUNkTE8zYVdOcnpDVUswR2NYaVV0azY0WnhjUHhMVHRtbHJXaXNzcHNNeXRIakVYMWJPVjFQTFkwLWVHVy02b2dnWTN4NEtUUW9KbkhVZ1Z4TjROMS1TNW83SGkwTDhMNzN2bzZsZ3V6Ti00S3RxQndPcmNzLXRjdEdYTW1Gc0Z6ckZJNUo0WHRDZGEzYkZLQXYyRE9sTmx4Y2VfSFNjSzhjRFlYTGpnOFNWTmk?oc=5","date":"2026-03-17","type":"pipeline","source":"Stock Titan","summary":"New hires at Forte Biosciences get options on 25,000 shares - Stock Titan","headline":"New hires at Forte Biosciences get options on 25,000 shares","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxPYUM3SDdEZHdFcHV1Y0pVckI2Y0RrVERCYVhEUS1lWUhNdUVObDY0VTFZbjEwM2R4dkt1a3hsTG50ck9ObnlMQXB5M2lkMm1yQ0pTSS12cnVWeG51V0tKU1JLbko2aXZ3M25UOFJGTkxUUWZ0RG0zb19hYmM1NHFucUZueE1POXJtb3QxSlczZmZzWC1LdDcyUHU2S3IyU29VSnJDWW9OZjJPdw?oc=5","date":"2026-03-12","type":"pipeline","source":"Medscape","summary":"Tachyphylaxis in Psoriasis: What’s Really Happening? - Medscape","headline":"Tachyphylaxis in Psoriasis: What’s Really Happening?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirAFBVV95cUxNaDV3UWdmTFhiVHZxZEp3VUhLOFo0bEIzNXlqam9kb3dEMlJEWjQ5cVQ4eVhIelJaVk85Z09tdTZkaUV2UlRudDd2eFludl9sbGlWVnBnX0N4YkE2ZDgwYWhheXVJNnhhSEpsalVHTHRIbGk4V3lEaEpUaDFSc294VDJaWDJaNXRkel85bWFiaFl1b25oOVVkaHpRdkY0dnY5aUhsLUVCQ3JibkJn?oc=5","date":"2026-02-09","type":"pipeline","source":"Stock Titan","summary":"Forte Biosciences chief lines up Guggenheim, TD Cowen, Barclays talks - Stock Titan","headline":"Forte Biosciences chief lines up Guggenheim, TD Cowen, Barclays talks","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikwFBVV95cUxQYWRyN1FITVBzYXpsYWFQMDR1T0Y2OWE4QWE1OC03dE1JdlJNQk05RFpMcVNkWE4wUjZFUmZWMFI5SGZKYjZ6N2dUeGtCRkJFTi1aZXV0SXZNbW9vdXNfaV9lejFkUTZpaU1ZOENCMDRqUTA5Sll5NkIzbWhrU2RmSmQ5Z2Y0UWVQSjlVM1RkQUNyR2c?oc=5","date":"2026-01-21","type":"pipeline","source":"BioWorld News","summary":"CD122’s double whammy makes for intriguing target - BioWorld News","headline":"CD122’s double whammy makes for intriguing target","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi5gFBVV95cUxNLTF5WUlFMHpSdHVCRHkwWGNZZFdRT05BOW5kLS1LendXUEpQbmU4T2p4dlRCLWlvNklaeDhOV3p0ZWR1UDhNMlBIWElmd1gyLVlkeEUyMFFXR29vLWF2Q0dLU3BkOGM3RFVkaXJ2UWJJLW1GS2NnMGVHblhmLXdxYi0yTFp0THRteVNFTFZXbk9XWTQ1NndManpyZmVGZFZGbE1nX1gtb1U5a0lETFlLVWhXT1lmekFTVmU2Z0FUcEpySFVTd09CUXI0eFExYzdzMXJpdkhpVk1pQU5hVUNhMmptb0xqZ9IB6wFBVV95cUxNNmFVck9Ta3V4MnlPWHpxV2s3YkRtVkN0eGdNTnJZUkZwTnQ1TE14eWVfLUE3VTIzaGh0UEZVaXdSMXJldEpMUWhQcEdNNXNQNWVjOVNsbGh3V1k4a2NPUGlyRmRqSFlVV0hvRXA3YjV3SHNyY3N6Z25yTlFYa1c3Y0tMamx5a3RGOTVmRWhhMVNOaGRkNlZGTDRrUmY0QU5OOHh0d01CcGd6UVpGdWdvbjB5T2kzdGZnVlhIM21jVFllYnNwRS0zd3EyVjNqM1k1YVR4UU9EcHl2X2FNNVFodVAtaWQ2ZkhhZXQ0?oc=5","date":"2026-01-03","type":"pipeline","source":"simplywall.st","summary":"Institutional investors may adopt severe steps after Forte Biosciences, Inc.'s (NASDAQ:FBRX) latest 15% drop adds to a year losses - simplywall.st","headline":"Institutional investors may adopt severe steps after Forte Biosciences, Inc.'s (NASDAQ:FBRX) latest 15% drop adds to a y","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxQVVhxNnIzLWZNbXEyZ2tCMnZwZ3JidXoyb1hlTUtjNmt2Wm9rYmtpWnVZc0xrOG5GbWgwdWtxakJZNzZlb2hpMU1pekZrTDM5Wi1qVHJiQ1laa3JEcjZ4S0g0U3prZXAzRkRKWXFSMkF1UlQ1cGdDVXpLSzFtOE1HemlZcEVsRS1pTnh0c3V1cGpXY0Q4anhvTE9ZcVV3a2JIYVRrV3BacnFFeVZxS0Nyd3Z6YldFakxmaXBudUQzUQ?oc=5","date":"2025-12-22","type":"pipeline","source":"Stock Titan","summary":"New Forte Biosciences hire receives options for 75,000 shares - Stock Titan","headline":"New Forte Biosciences hire receives options for 75,000 shares","sentiment":"neutral"},{"date":"2025-11-14","type":"earnings","source":"SEC EDGAR","summary":"10-Q filed with SEC: 10-Q","headline":"Quarterly Report (10-Q) Filed","sentiment":"neutral"},{"date":"2025-11-14","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxPU3ZOdTlaZDMxZ09IMkFUazlzVEtuS1A0RHg3b3dqTkQ0bjYtWFdjbC1KdjZPRWhZUXJORmhwUnI0dThfLVZJVC1QSnktSUg4Mm5ZOVBPbVJOWnRTSmZFWXN1SldQV3VYYU82dEp5RXE2NU96SEpMVHVNYVh5aUMtbnZhVHQ4cTBYQ2xjX1lHZjZBcDdV?oc=5","date":"2025-08-14","type":"trial","source":"Yahoo Finance","summary":"Vitiligo Clinical Trial Pipeline Accelerates as 18+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight - Yahoo Finance","headline":"Vitiligo Clinical Trial Pipeline Accelerates as 18+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveIn","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_2":1},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":{"source":"sec_edgar+yahoo","revenue":36000,"revenuePeriod":"2019-12-31","revenueHistory":[{"value":36000,"period":"2019-12-31"},{"value":18036000,"period":"2018-12-31"},{"value":41000,"period":"2017-12-31"},{"value":49000,"period":"2016-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":45299000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-69375000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":76957000,"cashHistory":[],"totalAssets":82779000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}